Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer

Rákkutatás · Prostate cancer

Lutetium‑177‑PSMA‑617 demonstrated superior PSA decline and progression‑free survival compared with standard chemotherapies in metastatic castration‑resistant prostate cancer, yet toxicity such as nephrotoxicity and xerostomia limits its broader application.

Prostate cancer (PCa) is the most common tumor for men in the genital system. Despite several new therapies approved in the past decades, 34,700 patients die on a regular basis in 2023 in America. Recently radioisotopic therapies have shown the delightful results in the PCa treatment, which made FDA approved lutetium‑177 for adult patients with prostate‑specific membrane antigen (PSMA)-positive metastatic castrate‑resistant prostate cancer (mCRPC). Many other clinical trials are also in progress in various settings. Both monotherapy and combination studies are underway. However, because of several limitations existed in these clinical trials and alarmed long‑term nephrotoxicity of PSMA‑targeted therapy, we should be more prudent to this therapy. In this review, we evaluate the evolving clinical and preclinical landscape of PSMA‑targeted therapy, as well as the potential biomarkers for evaluating the therapeutic response.

PSMA‑targeted radionuclide therapy offers a promising treatment option for metastatic castration‑resistant prostate cancer, improving survival outcomes, yet concerns over long‑term nephrotoxicity and xerostomia limit its broader application.

Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.

Eredeti forrás

Kapcsolódó jelek